Navigation Links
invivodata Captures Symptom Relief Data in Endometriosis Trial
Date:9/25/2008

Neurocrine Biosciences Demonstrates Rapid and Significant Pain Reduction with Elagolix

PITTSBURGH, Sept. 25 /PRNewswire/ -- invivodata inc., the industry leader in electronic patient reported outcomes (ePRO) solutions and services for global clinical research, today announced that its DiaryPRO(R) field-based ePRO system was used to capture important secondary efficacy endpoint data in Neurocrine Biosciences' (Nasdaq: NBIX) PETAL study, a Phase II clinical trial of its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis.

Over 250 patients used invivodata's electronic diary twice daily to record the frequency and severity of endometriosis symptoms before, during, and after six months of treatment, using several different scales to measure dysmenorrhea and pelvic pain. Data captured on DiaryPRO helped Neurocrine demonstrate a clinically meaningful and statistically significant reduction in endometriosis pain from baseline among patients treated with elagolix.

"When conducting a clinical trial of this importance and magnitude, it's critical to choose a vendor that is knowledgeable about clinical development and easy to work with," said Chris O'Brien, MD, Chief Medical Officer at Neurocrine Biosciences. "invivodata's process for designing and implementing ePRO was comprehensive and straightforward, and easily fit within our clinical development timeline."

"The PETAL study represents an important step forward in Neurocrine's ongoing efforts to bring relief to patients suffering from endometriosis," said Doug Engfer, invivodata president and CEO. "We are thrilled to continue working with Neurocrine as they explore the full therapeutic potential of elagolix."

About invivodata inc.

invivodata combines behavioral science, information technology, and clinical research expertise to capture high quality clinical trial data directly from patients. invivodata's electronic Patient Reported Outcomes (ePRO) solutions, which are based on over 20 years of research, deliver reliable patient self-reported data by driving patient compliance with the protocol and eliminating recall biases that plague paper-based self-report data. invivodata's solutions include comprehensive trial-support services that facilitate the collection of ePRO data, and web-based access to study data and operational reports that give researchers and sponsors visibility into study progress and improve trial efficiencies. invivodata's solution has been used in more than 200 trials and is the industry-leading ePRO system in delivering primary efficacy data for FDA drug approvals. invivodata inc. is a privately held company with global headquarters in Pittsburgh, Pa., USA; its European headquarters is in London, England; and its technology development center is in Scotts Valley, Calif., USA. For more information visit http://www.invivodata.com.

For more information, contact:

invivodata inc.

Christine Tobin

Corporate Communications Specialist

(412) 390-3000, ext. 3502

ctobin@invivodata.com


'/>"/>
SOURCE invivodata inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
2. Screening for Ischemia in Asymptomatic Patients With Type 2 Diabetes: Five- Year Outcomes in the DIAD Study
3. n-3 PUFAs Reduce Mortality and Hospital Admissions in Patients With Symptomatic Heart Failure
4. Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients Day
5. Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
6. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
7. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
8. ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
9. Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
10. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
11. Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Dec 5, 2016 Research and Markets ... Market - Global Forecast to 2021" report to their offering. ... , , ... reach 17.27 billion by 2021, at a CAGR of 5.3% from 2016 ... growing number of obesity cases, increasing government spending on healthcare, and rising ...
(Date:12/5/2016)... PharmaBoardroom today releases its new 70 page Switzerland Healthcare & Life ... , , ... stakeholders crucial insight into Switzerland ; a country located ... of the world,s most important international health institutions as well as two ... number one ranking globally in terms of ease of doing business and ...
(Date:12/4/2016)... , Dec. 4, 2016 Blueprint ... in discovering and developing targeted kinase medicines for ... from its ongoing Phase 1 trial evaluating BLU-285, ... with advanced systemic mastocytosis (SM). Blueprint Medicines is ... of D816V mutant KIT. Approximately 90 to 95 ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... December 05, 2016 , ... Airy Jeanine is putting ... Songwriter-Producer Corey “Chorus” Gibson who has worked on hits by mega-artists like Rihanna, ... https://twitter.com/coreychorus , The sessions taking place in North Jersey’s Cybertime Studios ...
(Date:12/5/2016)... ... ... Shah MD, MBA has joined the Retina Group of New York (RGONY) specializing ... M. Maisel, MD and has been providing tertiary medical and surgical retinal care on Long ... expectations amongst her peers. Growing up in a family of doctors, Dr. Shah emulated ...
(Date:12/5/2016)... San Diego, CA (PRWEB) , ... December 05, 2016 , ... ... have seen and heard the dangers and downsides of patients who do not do ... devices. The field of cosmetic dermatology is in the midst of a renaissance and ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... won "Best Surgical Facial Rejuvenation" at the 2016 Anti-Aging & Beauty Awards ... , The Aesthetic & Anti-aging Medicine European Congress (AMEC) brings together ...
(Date:12/5/2016)... Columbus, OH (PRWEB) , ... December 05, 2016 ... ... novel engineering solution called the CardioQuick Patch® significantly improves the reproducibility and accuracy ... usability in various healthcare settings. , Over the last 60 years, studies ...
Breaking Medicine News(10 mins):